Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular Modeling and Simulations of Biologics.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Mechanisms of L-cysteine-mediated CO₂ hydrate nucleation: role of thermodynamic driving force and interfacial effects.

Journal of colloid and interface science·2026

Same author

High-throughput small-angle X-ray scattering reveals effective structure factor transitions linked to high-concentration antibody viscosity.

mAbs·2026

Same author

Understanding Size Distributions during Lipid Nanoparticle Manufacturing through Mechanistic Modeling.

ACS omega·2026

Same author

Modular Design of Vacuum Systems for Lyophilization.

Industrial & engineering chemistry research·2026

Same author

Molecular Modeling and machine learning for predicting high-concentration antibody viscosity.

Advanced drug delivery reviews·2026

Search research articles

Related Experiment Video

Updated: Nov 24, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Machine Learning Feature Selection for Predicting High Concentration Therapeutic Antibody Aggregation.

Pin-Kuang Lai¹, Amendra Fernando¹, Theresa K Cloutier¹

¹Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Journal of Pharmaceutical Sciences

|December 21, 2020

Summary

This summary is machine-generated.

Developing predictive models for therapeutic antibody aggregation is crucial. This study presents a feature selection framework enabling accurate aggregation prediction with minimal data, improving drug development.

Keywords:

Antibody aggregations Feature selections Machine learning Molecular dynamics simulations

More Related Videos

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Published on: August 16, 2019

Related Experiment Videos

Last Updated: Nov 24, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Published on: August 16, 2019

Area of Science:

Biopharmaceutical Development
Computational Chemistry
Protein Science

Background:

Protein aggregation poses significant challenges to the development, safety, and efficacy of therapeutic antibody-based drugs.
Accurate prediction of aggregation behavior during early development is highly desirable but often limited by data availability.
Machine learning (ML) techniques are powerful tools for predictive modeling but typically require substantial datasets.

Purpose of the Study:

To develop a rational feature selection framework for creating accurate predictive models of protein aggregation with limited data.
To apply this framework to predict the aggregation behavior of monoclonal antibodies (mAbs) at high concentrations.
To demonstrate the framework's utility in improving early-stage biopharmaceutical development.

Main Methods:

A rational feature selection framework was designed to identify key attributes for predictive modeling.
The framework was applied to a dataset of 21 approved monospecific monoclonal antibodies.
Linear models, nearest neighbors, and support vector regression were employed to predict aggregation behavior.

Main Results:

A linear model achieved a correlation coefficient of 0.71 on validation tests using only two selected features.
Nearest neighbors and support vector regression models demonstrated improved performance with correlation coefficients of 0.86 and 0.80, respectively.
The developed framework effectively predicts antibody aggregation with a small feature set.

Conclusions:

The proposed feature selection framework enables the development of accurate predictive models for antibody aggregation using limited data.
This approach can significantly aid in the early stages of therapeutic antibody development by anticipating aggregation issues.
The framework is adaptable for predicting other critical physical properties of therapeutic proteins.